Peter Rhode - 17 Nov 2023 Form 4 Insider Report for HCW Biologics Inc. (HCWB)

Role
Title of the Officer: Chief Scientific Officer and Vice President of Clinical Operations.
Signature
/s/ Nicole Valdivieso, as Attorney-in-Fact for Peter Rhode
Issuer symbol
HCWB
Transactions as of
17 Nov 2023
Net transactions value
+$2,100
Form type
4
Filing time
20 Nov 2023, 16:55:48 UTC
Previous filing
19 Jan 2022
Next filing
11 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCWB Common Stock Options Exercise $2,100 +15,000 +31% $0.1400* 63,500 17 Nov 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCWB Stock Option Grant (Right to Buy) Options Exercise $0 -15,000 -29% $0.000000 36,427 17 Nov 2023 Common Stock 15,000 $0.1400 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These option shares were part of a stock option grant covering 85,713 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant vested on May 30, 2022; and 35% of the total shares subject to the stock option grant vested on May 30, 2023, subject to the reporting person's continuous service through the applicable vesting date.

Remarks:

Title of the Officer: Chief Scientific Officer and Vice President of Clinical Operations.